Skip to Content

Adefovir Pregnancy and Breastfeeding Warnings

Adefovir is also known as: Hepsera

Adefovir Pregnancy Warnings

A pregnancy registry has been established to monitor fetal outcomes of pregnant women exposed to adefovir. Healthcare providers are encouraged to register patients by calling 1-800-258-4263 (USA).

Adefovir dipivoxil has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. There are no controlled data in human pregnancy. Adefovir dipivoxil is only recommended for use during pregnancy when benefit outweighs risk. There are no data concerning adefovir's effect on mother-to-infant hepatitis B virus transmission. Appropriate infant immunization is recommended to prevent neonatal acquisition of the virus.

See references

Adefovir Breastfeeding Warnings

There are no data on the excretion of adefovir dipivoxil into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. In addition, mothers coinfected with HIV should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. "Product Information. Hepsera (adefovir dipivoxil)." Gilead Sciences, Foster City, CA.

References for breastfeeding information

  1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL:" ([2011 Sep 14]):
  2. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6
  3. "Product Information. Hepsera (adefovir dipivoxil)." Gilead Sciences, Foster City, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.